Oncology Institute (TOIIW) Total Non-Current Liabilities (2020 - 2026)

Oncology Institute has reported Total Non-Current Liabilities for 7 years, with the latest figure at $184.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 16.17% year-over-year to $184.5 million; the trailing twelve-month figure through Mar 2026 stood at $184.5 million (up 16.17% YoY), and the FY2025 full-year result was $180.3 million, up 6.88% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $184.5 million, up from $180.3 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $184.5 million in Q1 2026, with the low at $62.6 million in Q2 2022.
• Historically, Total Non-Current Liabilities has averaged $145.9 million across 5 years, with a median of $151.8 million in 2023.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 646.25% — and 2025, when it fell 2.54%.
• Oncology Institute's Total Non-Current Liabilities stood at $134.5 million in 2022, then grew by 12.87% to $151.8 million in 2023, then increased by 11.12% to $168.7 million in 2024, then grew by 6.88% to $180.3 million in 2025, then grew by 2.3% to $184.5 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $184.5 million (Q1 2026), $180.3 million (Q4 2025), and $162.2 million (Q3 2025), per Business Quant data.